Oxaliplatin (NSC 266046)

製品コード:S1224 別名:L-OHP, Eloxatin

For research use only.

Oxaliplatin (NSC 266046, L-OHP, Eloxatin) is a DNA alkylating agent that activates autophagy. Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. DMF is recommended for dissolution. Solutions are best fresh-prepared.

Oxaliplatin (NSC 266046)化学構造

CAS No. 61825-94-3

サイズ 価格(税別)
JPY 13600
JPY 36800

代表番号: 03-5615-9297|電子メール:[email protected]
よく尋ねられる質問

文献中Selleckの製品使用例(158)

製品安全説明書

DNA/RNA Synthesis阻害剤の選択性比較

相関DNA/RNA Synthesis製品

生物活性

製品説明 Oxaliplatin (NSC 266046, L-OHP, Eloxatin) is a DNA alkylating agent that activates autophagy. Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. DMF is recommended for dissolution. Solutions are best fresh-prepared.
特性 This product is not recommended to be dissolved in dimethylsulfoxide (DMSO).[9]
ターゲット
DNA synthesis [1]
(RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, HT-144 cells)
体外試験

The main mechanism of action of Oxaliplatin is mediated through the formation of DNA–adducts. Oxaliplatin induces primary and secondary DNA lesions that lead to cell apoptosis. [1] Oxaliplatin is active against human melanoma cell lines C32 and G361 with IC50 of 0.98 mM and 0.14 mM, respectively. [2] Oxaliplatin effectively inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Caco2 MXHGeY5kfGmxbjDBd5NigQ>? NWTiXphTOzBxMUCwxsDPxE1? NWXPUotnOTcEoHi= NXfxTHNGTE2VTx?= MkjJZYN1cX[jdHXzJG5z\jJ? NELCWog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW1OlQyPSd-MkS1OVY1OTV:L3G+
Caco2  M4H4c2Z2dmO2aX;uJGF{e2G7 MXKzM|ExNzNyIN88US=> MX:xOkBp NE\rV4lFVVOR MnXibY5kemWjc3XzJJRp\SCvUl7BJIxmfmWuczDv[uKhSUuUMVOxMEBPWU9zLDDIU{0yNCCPUmCyMOKh[W6mTWLQN:Kh\G:|ZT3k[ZBmdmSnboTsfS=> NEXPW5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW1OlQyPSd-MkS1OVY1OTV:L3G+
Caco2  M3[4emZ2dmO2aX;uJGF{e2G7 MmXRN|DDqM7:TR?= MVmyOEBp M3jhbGROW09? MVfpcoR2[2W|IITo[UBmgHC{ZYPzbY9vKG:oIFjPMVEtKEGNUkHDMEBidmRiTmHPNS=> MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV3NkSxOUc,OjR3NU[0NVU9N2F-
SW620 NGDHcHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYf3S2F7OTBvN{CgcYcwVA>? MmH1NlQwPDhxN{KgbC=> M1fiWYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M{TMO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkS2N|A2Lz5{NE[0OlMxPTxxYU6=
SW480  M1nvZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorFOFghcMLi NFzMOXlKSzVyPUKwMlghfWdxbVy= NWfuToxjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3NlA3PzVpPkK0O|IxPjd3PD;hQi=>
HCT116 NGrQe4RHfW6ldHnvckBCe3OjeR?= NIfpO48zNzViwsXN M4n2XFI1NzR6IHi= Mnmwd5VxeHKnc4Pld{B{fXK4aY\pckBuWk6DIHX4dJJme3Orb36= MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd4MUSxNUc,OjR5NkG0NVE9N2F-
HT-29 M3GxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYCxxsDPxE1? M2nmc|AuPzJiaB?= MkDybY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> MmH3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUe0OVEoRjJ2OUm3OFUyRC:jPh?=
SW480 NWjmPGFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHyUFVSOcLizszN M3rXN|AuPzJiaB?= M1HHOYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgeIlu\SCmZYDlcoRmdnRibXHucoVz M176RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUm3OFUyLz5{NEm5O|Q2OTxxYU6=
HUVEC NUTHcVc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTFzLkOwxsDDucLiMT6wNkDPxE1? MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNyN{S0PEc,OjV|MEe0OFg9N2F-
HEK293 MoK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn62TWM2OD16LkiyxsDDucLiNT61PUDPxE1? M1\CSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{C3OFQ5Lz5{NUOwO|Q1QDxxYU6=
HT-29 Ml7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHaTWM2OD53MDFOwG0> NYnXRYU2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNFc1PDhpPkK1N|A4PDR6PD;hQi=>
HCT-116 M1jEcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3myNmlEPTB;Nj6yOOKhyrIEoEKuPVch|ryP MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNyN{S0PEc,OjV|MEe0OFg9N2F-
MCF-7 NVLGTFdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUW0WXZrUUN3ME2xOE4zPMLiwsJCpFEvQDJizszN NXTheVRuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNFc1PDhpPkK1N|A4PDR6PD;hQi=>
HepG2 M3H2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTF2LkK0xsDDucLiMT64NkDPxE1? NUeyeGgyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNFc1PDhpPkK1N|A4PDR6PD;hQi=>
A549 NEDaVHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HH[WlEPTB;NUGuNFjDqMLzwrCxNE46PiEQvF2= MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNyN{S0PEc,OjV|MEe0OFg9N2F-
SGC7901 MknaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTJzLkezxsDDucLiMz6wPEDPxE1? MnnpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|MEe0OFgoRjJ3M{C3OFQ5RC:jPh?=
COC1 NHTr[IlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDVOpE6UUN3ME20Ok4zOMLiwsJCpFMvOTRizszN M2fJXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{C3OFQ5Lz5{NUOwO|Q1QDxxYU6=
HCT116  MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M361NVczKGkEoB?= Ml3nTWM2OD14LkKzxtExNjd3INM1[{9uVA>? M{LTRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{[wOlMyLz5{NUO2NFY{OTxxYU6=
SW480 NIL6SVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkO0O|IhcMLi M4\UfmlEPTB;MUCuO:KyOi5{NjFCuYcwdUx? M{TZPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{[wOlMyLz5{NUO2NFY{OTxxYU6=
MIAPaCa-2 NXvDTJdqTnWwY4Tpc44hSXO|YYm= MojmNlXjiIoEtV2= MkjJNlQwPDhiaB?= NFTCTo9qdmS3Y3XzJINt\WG4YXflJI9nKFCDUmCsJINie3Cjc3WtPUwh[2G|cHHz[U05KGGwZDDjZZNx[XOnLURCpC=> M4jEXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NES0PVE1Lz5{NUS0OFkyPDxxYU6=
Panc-1 NEm3c|FHfW6ldHnvckBCe3OjeR?= MnPzNlXjiIoEtV2= M2DjNVI1NzR6IHi= MVvpcoR2[2W|IHPs[YF3[WenIH;mJHBCWlBuIHPhd5Bie2VvOTygZ4F{eGG|ZT24JIFv\CClYYPwZZNmNTQEoB?= NEfoXmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS0OFkyPCd-MkW0OFQ6OTR:L3G+
MIAPaCa-2 NWPWVnk6SXCxcITvd4l{KEG|c3H5 NUnEdFNsOjYkgJpCuW0> M3jKXFI1KGh? NV3pZm1QcW6mdXPld{BieG:ydH;zbZMhcW5iYTDzfY5memerc4TpZ{Bu[W6wZYKgZ49u[mmwZXSge4l1cCCZQR?= NX\iOZQ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0OFQ6OTRpPkK1OFQ1QTF2PD;hQi=>
Panc-1 NVLUS2FVSXCxcITvd4l{KEG|c3H5 M4izWVI26oDLwsXN NH3Md3ozPCCq MXXpcoR2[2W|IHHwc5B1d3OrczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC M3XOdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NES0PVE1Lz5{NUS0OFkyPDxxYU6=
HPDE M4jSSWNmdGxiVnnhZoltcXS7IFHzd4F6 MXyyOU82OCEQvF2= NIS1Vo4zPC92ODDo MnfRbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCxZjDQR{Bk\WyuczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC NHHzemc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS0OFkyPCd-MkW0OFQ6OTR:L3G+
SW1990 NXfUTWpWS2WubDDWbYFjcWyrdImgRZN{[Xl? M{fPTlI2NzVyIN88US=> NYnoe3hsOjRxNEigbC=> NEPUd|JqdmirYnn0d{Bxem:uaX\ldoF1cW:wIH;mJHBEKGOnbHzzJIlvKGFic4nu[ZJocXO2aXOgcYFvdmW{IHPvcYJqdmWmIIfpeIghX0F? NV7Ib5pQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0OFQ6OTRpPkK1OFQ1QTF2PD;hQi=>
MIAPaCa-2 NFXuZVVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MonlNlUwPTBizszN NWL3VZNbOjRxNEigbC=> NWfIWWdLcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDv[kBRSyClZXzsd{BqdiCjIIP5coVz\2m|dHnjJI1idm6ncjDjc41jcW6nZDD3bZRpKFeD M1XSOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NES0PVE1Lz5{NUS0OFkyPDxxYU6=
Panc-1 NYS2S3R2S2WubDDWbYFjcWyrdImgRZN{[Xl? Mo\zNlUwPTBizszN NVvHUolUOjRxNEigbC=> M4PGXolvcGmkaYTzJJBzd2yrZnXyZZRqd25ib3[gVGMh[2WubIOgbY4h[SC|eX7ldodqe3SrYzDtZY5v\XJiY3;tZolv\WRid3n0bEBYSQ>? MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR2NEmxOEc,OjV2NES5NVQ9N2F-
A549/CDDP MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{KyWWlEPTB;MUiuOkDDuSBzLkKg{txO NGL5dGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[yOVI1Oyd-MkW2NlUzPDN:L3G+
A549 M2[wdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjCbppJUUN3ME21MlghyrFiMD62JO69VQ>? MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NUK0N{c,OjV4MkWyOFM9N2F-
SW480 NGW4U4dHfW6ldHnvckBCe3OjeR?= Mn7hNVDjiIoEtXevcYw> NIjkRXEzPOLCiXi= NHyyVXRmdmijbnPld{Bk\WyudXzhdkBifXSxcHjh[4lkKG[udYi= NF3zXFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe0PVQzOCd-MkW3OFk1OjB:L3G+
SW620 NWrpflFUTnWwY4Tpc44hSXO|YYm= MVyxNQKBkcL3Zz;tcC=> M{\YcFI16oDLaB?= MUTlcohidmOnczDj[YxtfWyjcjDheZRweGijZ3njJIZtfXh? NH:0OVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe0PVQzOCd-MkW3OFk1OjB:L3G+
SW480 M3zIPWZ2dmO2aX;uJGF{e2G7 MlzINVDjiIoEtXevcYw> NUTN[HV5OjUkgJno NXLBTIg{cW6lcnXhd4V{KEyFMz3JTUBi[2O3bYXsZZRqd25iYX7kJIRm[3KnYYPld{BRPjJiZYjwdoV{e2mxbh?= NHS2O249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe0PVQzOCd-MkW3OFk1OjB:L3G+
SW620 NU\t[29uTnWwY4Tpc44hSXO|YYm= M{G2b|Ex6oDLwsXnM41t MXiyOQKBkWh? MoDNbY5kemWjc3XzJGxEOy2LSTDhZ4N2dXWuYYTpc44h[W6mIHTlZ5Jm[XOnczDQOlIh\XiycnXzd4lwdg>? Mn\rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NEm0NlAoRjJ3N{S5OFIxRC:jPh?=
HT-29 NUH2cVFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIf4dmlKSzVyPUWuNlIh|ryP MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4MUS3PUc,OjV5NkG0O|k9N2F-
SNU-175 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHKd5dGUUN3ME2xMlUyKM7:TR?= NE[1VGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2NVQ4QSd-MkW3OlE1Pzl:L3G+
COLO-320DM MoDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTVwM{ig{txO NUHqPWZ[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OlE1PzlpPkK1O|YyPDd7PD;hQi=>
DLD-1 M{e4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\yN4RkUUN3ME24MlY2KM7:TR?= M4TBWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{[xOFc6Lz5{NUe2NVQ4QTxxYU6=
DiFi NFXNW|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHKTWM2OD1zMD65OUDPxE1? MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4MUS3PUc,OjV5NkG0O|k9N2F-
HCT-15 MkXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUGxSVBvUUN3ME24MlY1KM7:TR?= NEn4ZVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2NVQ4QSd-MkW3OlE1Pzl:L3G+
SCM-1 NIX0WVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XneWlEPTB;MUeuOUDPxE1? Mn3HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5OEmwOVcoRjJ3N{i5NFU4RC:jPh?=
TMK-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTJ{Lk[g{txO MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd6OUC1O{c,OjV5OEmwOVc9N2F-
MKN-45 M2\1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfJfHJ7UUN3ME2xOE4xKM7:TR?= MkDUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5OEmwOVcoRjJ3N{i5NFU4RC:jPh?=
AGS M4HvOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTWcIhKSzVyPUGwMlYh|ryP NIXEb2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe4PVA2Pyd-MkW3PFkxPTd:L3G+
S3 MmLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTV|LkWgxtEhOS53IN88US=> M1;PblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OECxNFA4Lz5{NUiwNVAxPzxxYU6=
SiHa Mn;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHqXlh3UUN3ME2wMlghyrFiMD6xJO69VQ>? NUPUPIY5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NFExODdpPkK1PFAyODB5PD;hQi=>
HT-29 NEL2fYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLSeGR4UUN3ME2zOU43KM7:TR?= NGnjWpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCwN|A5PSd-Mk[wNFMxQDV:L3G+
DLD-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTN{LkKg{txO M{DwbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MECzNFg2Lz5{NkCwN|A5PTxxYU6=
HT29 MlOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;RVGlEPTB;NkOg{txOKMLzIEG4 M{TTelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEC0NFg1Lz5{NkCwOFA5PDxxYU6=
MC38 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3m3[WlEPTB;MkOg{txOKMLzIEK= M3GxSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEC0NFg1Lz5{NkCwOFA5PDxxYU6=
SW620 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLoTWM2OD1|Lk[4JO69VQ>? NIHjdGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyN|A5PSd-Mk[wNlMxQDV:L3G+
SW480 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfkTWM2OD1{Lki2JO69VQ>? NWXxfI8xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlMxQDVpPkK2NFI{ODh3PD;hQi=>
RKO MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXO2flRUUUN3ME2xMlI{KM7:TR?= NES3fFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyN|A5PSd-Mk[wNlMxQDV:L3G+
LoVo MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDOZWFKSzVyPUGuNkDPxE1? MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{M{C4OUc,OjZyMkOwPFU9N2F-
KM12 M{L3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TDVmlEPTB;ND6zO{DPxE1? NGXuOVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyN|A5PSd-Mk[wNlMxQDV:L3G+
HCT116p53- MkjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzCZWk2UUN3ME2xMlA5KM7:TR?= M1KwfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN|A5PTxxYU6=
HCT116 NFy0VFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHf1VYRKSzVyPUGuNFQh|ryP MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{M{C4OUc,OjZyMkOwPFU9N2F-
HCT15 NICyZotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPjTWM2OD1zLkSzJO69VQ>? M3vEXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN|A5PTxxYU6=
HT29 NGTwN4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFK1N|VKSzVyPUKuOlkh|ryP M{LQbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN|A5PTxxYU6=
DLD1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPwZ5VJUUN3ME2yMlAyKM7:TR?= MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{M{C4OUc,OjZyMkOwPFU9N2F-
Colo205 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzn[pNjUUN3ME2zMlM{KM7:TR?= NYPYVI5SRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlMxQDVpPkK2NFI{ODh3PD;hQi=>
BE Ml21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NICzTWdKSzVyPUOuN|Mh|ryP MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{M{C4OUc,OjZyMkOwPFU9N2F-
CT26  NIPUc5lE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MmfIOEBuVQ>? MXO0PEBpyqB? M4Hm[YRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTD0c{A2Oy5{JR?= MnnqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{ewNVIoRjJ4MUO3NFEzRC:jPh?=
CT26  M3PNRWZ2dmO2aX;uJGF{e2G7 MYi0JI1O MkTLOFghcMLi MX3pcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Yx{KG:oIHH1eI9xcGGpeT3y[YxifGWmIIDyc5RmcW6|LDDzeYNpKGG|IFzDN{1KUSxiQnXjcIlvOSCjbnSgRXRIPQ>? NEGy[FU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzO|AyOid-Mk[xN|cxOTJ:L3G+
CT26  M4Tqd2Z2dmO2aX;uJGF{e2G7 NV;Wd4tVPCCvTR?= M4TETVQ5KGkEoB?= MkjrbY5lfWOnczDheZRweGijZ4m= MlPpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{ewNVIoRjJ4MUO3NFEzRC:jPh?=
SK-OV-3 MV;GeY5kfGmxbjDBd5NigQ>? M1mwZVUxKM7:TdMg MnnBOFghcMLi NEW3XVBxem:vb4Tld{B{\W6|aYTpeol1gSCxZjDveoFzcWGwIHPhdoNqdm:vYTD0c{BPUyClZXzsMY1m\GmjdHXkJIN6fG:ueYPpdy=> MoTJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{i2O|EoRjJ4MUO4OlcyRC:jPh?=
OVCAR-5 NY[zU3Z3TnWwY4Tpc44hSXO|YYm= NHu1NYszOCEQvF5CpC=> NYHTPVU1OjSq NFvWdIhxem:vb4Tld{B{\W6|aYTpeol1gSCxZjDveoFzcWGwIHPhdoNqdm:vYTD0c{BPUyClZXzsMY1m\GmjdHXkJIN6fG:ueYPpdy=> NUjibG5wRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN|g3PzFpPkK2NVM5PjdzPD;hQi=>
PA-1 NFLVTIZHfW6ldHnvckBCe3OjeR?= NF3ufI0yOCEQvF5CpC=> MYiyOIg> NHnYeGJxem:vb4Tld{B{\W6|aYTpeol1gSCxZjDveoFzcWGwIHPhdoNqdm:vYTD0c{BPUyClZXzsMY1m\GmjdHXkJIN6fG:ueYPpdy=> NF3HPHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzPFY4OSd-Mk[xN|g3PzF:L3G+
SK-OV-3 M4Xl[mZ2dmO2aX;uJGF{e2G7 MlvxOVAh|ryP M2T2Wlk3KGh? NIHZWZN2eC2{ZXf1cIF1\XNidHjlJJN1emW|czDsbYdidmS|IH\vdkBPUyClZXzsMYFkfGm4YYTpcochemWlZYD0c5J{KGGwZDDUVmFKVCC{ZXPldJRwenN? MlLWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{i2O|EoRjJ4MUO4OlcyRC:jPh?=
OVCAR-5 MVHGeY5kfGmxbjDBd5NigQ>? Mlm0N|Ah|ryP Ml;COFhp MX\1dE1z\We3bHH0[ZMhfGinIIP0doV{eyCuaXfhcoR{KG[xcjDOT{Bk\WyuLXHjeIl3[XSrbnegdoVk\XC2b4LzJIFv\CCWUlHJUEBz\WOncITvdpM> MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF|OE[3NUc,OjZzM{i2O|E9N2F-
PA-1 MXrGeY5kfGmxbjDBd5NigQ>? MnnJNVAh|ryPwrC= NHTOUW01QGh? NGnhSmd2eC2{ZXf1cIF1\XNidHjlJJN1emW|czDsbYdidmS|IH\vdkBPUyClZXzsMYFkfGm4YYTpcochemWlZYD0c5J{KGGwZDDUVmFKVCC{ZXPldJRwenN? MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF|OE[3NUc,OjZzM{i2O|E9N2F-
SK-OV-3 MkfGSpVv[3Srb36gRZN{[Xl? MoXSOVAh|ryP MXe5OkBp MWP0dolo\2W{ZYOgeIhmKHC{b3T1Z5Rqd25ib3[geJlx\SCLIFnGUpMh[W6mIHPo[Y1wc2mwZYO= MnrrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{i2O|EoRjJ4MUO4OlcyRC:jPh?=
OVCAR-5 MYDGeY5kfGmxbjDBd5NigQ>? NVzzT45xOzBizszN NUDKfpVOPDiq M1jZZpRzcWepZYLld{B1cGVicILv[JVkfGmxbjDv[kB1gXCnIFmgTWZPeyCjbnSgZ4hmdW:taX7ldy=> M13Rb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO4OlcyLz5{NkGzPFY4OTxxYU6=
PA-1 MkDwSpVv[3Srb36gRZN{[Xl? MX2xNEDPxE4EoB?= M2PIXlI1cA>? MXj0dolo\2W{ZYOgeIhmKHC{b3T1Z5Rqd25ib3[geJlx\SCLIFnGUpMh[W6mIHPo[Y1wc2mwZYO= M1XvclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO4OlcyLz5{NkGzPFY4OTxxYU6=
SK-OV-3 M3TaU2NmdGxiVnnhZoltcXS7IFHzd4F6 MmnxNE0yODBizszN NFnzOoczPC92OD:3NkBp MojTbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MlvLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{i2O|EoRjJ4MUO4OlcyRC:jPh?=
OVCAR-5 NYjxW29XS2WubDDWbYFjcWyrdImgRZN{[Xl? NV7Se4w6OC14MDFOwG0> NEXLUZQzPC92OD:3NkBp MUXpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF|OE[3NUc,OjZzM{i2O|E9N2F-
PA-1 M3zyW2NmdGxiVnnhZoltcXS7IFHzd4F6 M3XvT|AuOjBizszN NF\re3ozPC92ODDo NVTy[5JucW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NFOzWWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzPFY4OSd-Mk[xN|g3PzF:L3G+
HCT116 NEHjRXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTBwNEJCpOKyyqByLkCyJO69VQ>? MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF2OEW5Okc,OjZzNEi1PVY9N2F-
HT29 MlnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTBwOElCpOKyyqByLkKg{txO MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF2OEW5Okc,OjZzNEi1PVY9N2F-
SNU-387 MmDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LTVmlEPTB;MkZCpOKyyqB{Lkeg{txO NGn1VJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG2NFQzQSd-Mk[xOlA1Ojl:L3G+
SNU-475 NHzMV5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|Ux97zgM{Cg{txO M{HJelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MU[wOFI6Lz5{NkG2NFQzQTxxYU6=
Hep-G2 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH74XlNKSzVyPUGzMlHDqMLzwrCxMlYh|ryP Ml;3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzNkC0NlkoRjJ4MU[wOFI6RC:jPh?=
SNU-398 M4W3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTZwNdMgxtHDqDFwMTFOwG0> NYP6NY9QRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xOlA1OjlpPkK2NVYxPDJ7PD;hQi=>
LoVo  NHPkfYFHfW6ldHnvckBCe3OjeR?= NVP3b2dTOS93IN88US=> MVSyOE81QCCq M2fsN4lv\HWlZYOgeJJidnOlcnnweIlwdmGuIILldJJme3Orb36gc4YhTFWWLV6= MlLOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{MEi1NlMoRjJ4MkC4OVI{RC:jPh?=
HCT116 p53+/+ M{fZPWZ2dmO2aX;uJGF{e2G7 MUOxM|Uh|ryP NVnZdYgzOjRxNEigbC=> NWDySG97cW6mdXPld{B1emGwc3PybZB1cW:wYXygdoVxemW|c3nvckBw\iCGVWStUi=> Mk\3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{MEi1NlMoRjJ4MkC4OVI{RC:jPh?=
MDA-MB-231 NUPSS|A5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTaTWM2OD1{Mz6xJOKyKDBwMTFOwG0> NUPpbnNERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yNVE2QTFpPkK2NlEyPTlzPD;hQi=>
MCF-7 M37IW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkP2TWM2OD1zNT60JOKyKDBwMzFOwG0> MnH2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{MUG1PVEoRjJ4MkGxOVkyRC:jPh?=
SK-BR-3 Mm\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEe3UJNKSzVyPUOxMlAhyrFiMD6xJO69VQ>? M3\qWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkGxOVkyLz5{NkKxNVU6OTxxYU6=
LoVo NHHUUVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLwWnZjPDhiaNMg NGnKSoNKSzVyPUm0Mlg{KM7:TR?= MnPJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{Nkm3OVkoRjJ4Mk[5O|U6RC:jPh?=
HCT116 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXW0PEBpyqB? NYKxfoxXUUN3ME2xNU45PiEQvF2= NVzYVGY1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yOlk4PTlpPkK2NlY6PzV7PD;hQi=>
SW480 NVG4[nI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHhc3BoPDhiaNMg M1X4WGlEPTB;MT64O{DPxE1? MoLUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{Nkm3OVkoRjJ4Mk[5O|U6RC:jPh?=
CaES-17 M3rQPGN6fG:2b4jpZ4l1gSCDc4PhfS=> M3zoOVDjiJNzNkFCpO69VQ>? NGf2cmY1QMLiaB?= NEDyRXVKSzVyPUWuOeKhyrIEoECuNkDPxE1? MlzCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ2N{S2PVMoRjJ4NEe0Olk{RC:jPh?=
HKESC-2 NH;PSGtEgXSxdH;4bYNqfHliQYPzZZk> MXuw5qCUOTZywrFOwG0> M3H5TlQ5yqCq MUHJR|UxRTVwONMgxtHDqDBwNTFOwG0> Ml3vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ2N{S2PVMoRjJ4NEe0Olk{RC:jPh?=
アッセイ
Methods Test Index PMID
Western blot VEGFR-1 / NRP-1 ; p-AKT(Ser473) / AKT / PTEN / p-Src(Tyr416) ; p-Src(Y418) / p-FAK(Y861) 18790786 19383922
Immunofluorescence E-cadherin / Vimentin ; ATXN2L / G3BP1 30787271
Growth inhibition assay Cell viability 28339092
体内試験

A weekly i.p. injection of Oxaliplatin at 10 mg/kg to nude mice bearing hepatocellular HCCLM3 tumors significantly reduces tumor volume and apoptotic index. [6] Oxaliplatin (5mg/kg, i.v. on days 1, 5 and 9) is active on T-leukemia-lymphoma L40 AKR with T/C of 1.77. Oxaliplatin is also efficient on intracerebrally grafted L1210 leukemia, MA 16-C xenografts, B16 melanoma xenografts, Lewis lung xenografts and C26 colon carcinoma xenografts. [7] Oxaliplatin induces impairment of retrograde neuronal transport in mice. [8]

お薦めの試験操作(参考用のみ)

細胞試験:

[4]

  • 細胞株:RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2 and HT-144 cell lines
  • 濃度: ~100 μM
  • 反応時間:48 hours
  • 実験の流れ:

    The cytotoxicity studies are carried out with the sulforhodamine-B microculture colorimetrie assay. Typically, cells are plated into 96-well plates on day 0 and exposed to Oxaliplatin on day 1; the sulforhodamine-B assay is carried out 48 h after Oxaliplatin exposure. The plates are incubated at 37 °C in 5% CO2 and 100% relative humidity at all times except when adding Oxaliplatin and during the final assay period. The initial number of cells plated for the assay ranged from 2-20 × 103 cells/50 /nL/well. The numbers of cells for plating and the drug exposure time are based on pilot studies using the criteria that (a) the cells in control wells are still in the log phase of growth on the day of the assay; (b) the maximum absorbance for the untreated controls on the day of the assay is in the range of 1.0 to 1.5; and (c) cells go through >2 doublings during the drug exposure. Eight wells are used per concentration. The plates are read at 570 and/or 540 nm using a Biotek Instruments model EL309 microplate reader interfaced with an IBM PC-compatible computer. The data are transferred and transformed into a LOTUS 1-2-3 format by the computer program DATALOG, and survival fractions are calculated by comparing the drug treated with control

動物試験:

[6]

  • 動物モデル:Human hepatocellular carcinoma xenografts HCCLM3
  • 投薬量:10 mg/kg
  • 投与方法:A weekly i.p. injection

溶解度 (25°C)

体外

化学情報

分子量 397.29
化学式

C8H14N2O4Pt

CAS No. 61825-94-3
保管 2 years 4°C(in the dark) powder
Smiles C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]

投与溶液組成計算機(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)

mg/kg g μL

ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)

% DMSO % % Tween 80 % ddH2O
%DMSO %

計算結果:

投与溶媒濃度: mg/ml;

DMSOストック溶液調製方法: mg 試薬を μL DMSOに溶解する(濃度 mg/mL, 注:濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法:Take μL DMSOストック溶液に μL PEG300,を加え、完全溶解後μL Tween 80,を加えて完全溶解させた後 μL ddH2O,を加え完全に溶解させます。

投与溶媒調製方法:μL DMSOストック溶液に μL Corn oil,を加え、完全溶解。

注意:1.ストック溶液に沈殿、混濁などがないことをご確認ください;
2.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

便利ツール

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05322590 Not yet recruiting Drug: BXQ-350|Other: Placebo Metastatic Colorectal Carcinoma|Neuropathy Bexion Pharmaceuticals Inc.|ICON plc August 2022 Phase 1|Phase 2
NCT05031975 Not yet recruiting Drug: Irinotecan|Drug: Temozolomide Colorectal Cancer Fondazione IRCCS Istituto Nazionale dei Tumori Milano June 1 2022 Phase 2
NCT05068531 Recruiting -- Colorectal Cancer Metastatic Centre hospitalier de l''Université de Montréal (CHUM)|Exactis Innovation|Chaire Roger Des Groseillers d''oncologie chirurgicale HBP de l''Université de Montréal|Canexia Health June 2022 --
NCT05025826 Recruiting Other: Phycocare|Other: Placebo Metastatic Gastric Cancer Nantes University Hospital|Algosource April 1 2022 Not Applicable
NCT05251727 Recruiting Drug: thrombomodulin alfa|Drug: Placebo Chemotherapy-induced Peripheral Neuropathy Veloxis Pharmaceuticals March 24 2022 Phase 1
NCT04158349 Terminated Drug: Oxaliplatin|Drug: mFOLFIRI Colorectal Cancer|Appendiceal Cancer|Peritoneal Carcinoma University of Utah March 22 2021 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください

よくある質問(FAQ)

質問1:
Is it ok to dissolve Oxaliplatin in DMSO?

回答
Even though cis-platin is soluble in DMSO, the use of DMSO to dissolve cis– or trans-diamminedichloroplatinum (DDP) in biological studies is strongly discouraged. The DMSO inserts itself into the ligand and inactivates platin-containing compounds. DMF is a much better choice than DMSO.

Tags: Oxaliplatin (NSC 266046)を買う | Oxaliplatin (NSC 266046) ic50 | Oxaliplatin (NSC 266046)供給者 | Oxaliplatin (NSC 266046)を購入する | Oxaliplatin (NSC 266046)費用 | Oxaliplatin (NSC 266046)生産者 | オーダーOxaliplatin (NSC 266046) | Oxaliplatin (NSC 266046)化学構造 | Oxaliplatin (NSC 266046)分子量 | Oxaliplatin (NSC 266046)代理店